Mprila 30mg

Mprila 30mg is a medication used to treat:

• Psoriatic Arthritis (PsA): a chronic autoimmune disease that causes inflammation, stiffness, and pain in the joints, as well as skin and nail symptoms
• Moderate to Severe Plaque Psoriasis: a chronic autoimmune disease that causes inflammation and thickening of the skin

Composition: Each tablet of Mprila contains 30mg of Apremilast (an active pharmaceutical ingredient), a phosphodiesterase 4 (PDE4) inhibitor.

Mechanism of Action: Apremilast works by:

• Inhibiting the activity of phosphodiesterase 4, which is an enzyme that plays a role in the production of inflammatory cytokines
• Reducing the production of pro-inflammatory cytokines, which are proteins that promote inflammation and tissue damage
• Modulating the immune response to reduce inflammation and joint damage

Dosage: The recommended dose of Mprila is:

• 30mg twice daily, taken with or without food
• The dose should be adjusted according to patient response and tolerance

Side Effects: Common side effects of Mprila include:

• Nausea
• Diarrhea
• Headache
• Fatigue
• Insomnia
• Abdominal pain
• Increased risk of infections

Rare but serious side effects include:

• Severe allergic reactions (e.g. anaphylaxis)
• Blood disorders (e.g. agranulocytosis, neutropenia)
• Liver damage or liver failure
• Pancreatitis (e.g. inflammation of the pancreas)
• Interstitial lung disease (e.g. scarring of the lungs)

Recommendation: Mprila is recommended for patients with PsA or moderate to severe plaque psoriasis who have not responded to other treatments or who have had unacceptable side effects. Patients with kidney disease or other medical conditions that may affect their ability to respond to treatment should be closely monitored while taking Mprila.

Important Note:

• Mprila should be used under the guidance of a healthcare provider with experience in the treatment of PsA or moderate to severe plaque psoriasis.
• Patients should be advised to report any symptoms of hypersensitivity reactions, such as rash, itching, swelling, or difficulty breathing.
• Mprila may interact with other medications, such as warfarin or antacids. Patients should inform their healthcare provider of all medications they are taking before starting Mprila therapy.
• Women of childbearing potential should use effective contraception while taking Mprila and for at least 2 years after stopping treatment.

Special Precautions:

• Patients with liver disease should be closely monitored while taking Mprila.
• Patients with kidney disease should be closely monitored while taking Mprila.
• Patients with a history of blood disorders should be closely monitored while taking Mprila.
• Pregnant or breastfeeding women should consult their healthcare provider before taking Mprila.

Indications:

• Psoriatic Arthritis
• Moderate to Severe Plaque Psoriasis

Contraindications:

• Pregnancy
• Breastfeeding
• Severe liver disease
• Severe kidney disease
• Blood disorders (e.g. agranulocytosis, neutropenia)

Note: The above information is a general summary and is not intended to provide individualized advice or recommendations. It is always best to consult a healthcare provider for personalized guidance on the use of Mprila 30mg Apremilast 30mg Tablet.